Skip to main content
SpringerLink
Log in

Risk-Benefit Assessment of Amiodarone in the Treatment of Cardiac Arrhythmias

  • Review Article
  • Risk-Benefit Assessment
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Cardiac arrhythmias are a cause of significant morbidity and mortality in patients with cardiac disease, and thus represent a major management problem. The recognition that antiarrhythmic drugs have the potential to aggravate as well as to attenuate arrhythmias has prompted clinicians to reconsider treatment strategies and weigh the benefits of treatment against the risks. In this context, amiodarone has emerged as an effective antiarrhythmic agent and when used at the lowest effective dose has an acceptable side effect profile. This review focuses on the current clinical usage of amiodarone in a broad variety of cardiac arrhythmias, and addresses the risk-benefits arising from its use. It further discusses the current position of amiodarone in the management of sudden cardiac death.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Adams PC, Holt DW, Storey GCA, Morley AR, Campbell RWF. Amiodarone and its desethyl metabolite: tissue distribution and morphological changes during chronic therapy. Circulation 72: 1064–1075; 1985

    Article  PubMed  CAS  Google Scholar 

  • Alfonso F, Frenneaux M, McKenna WJ. Clinical sustained monomorphic ventricular tachycardia in hypertrophic cardiomyopathy: association with left ventricular apical aneurysm. British Heart Journal 61: 178–181, 1989

    Article  PubMed  CAS  Google Scholar 

  • Anastasiou-Nana M, Levis GM, Moulopoulos S. Pharmacokinetics of amiodarone after intravenous and oral administration. International Journal of Clinical Pharmacology Therapy and Toxicology 20: 524–529, 1982

    CAS  Google Scholar 

  • Andreasen F, Agerback H, Bjerregaard P, Gotzsche H. Pharmacokinetics of amiodarone after intravenous and oral administration. European Journal of Clinical Pharmacology 19: 293–299, 1981

    Article  PubMed  CAS  Google Scholar 

  • Beukema WP, Graboys TB. Spontaneous disappearance of blue-grey pigmentation during amiodarone therapy (out of the blue). American Journal of Cardiology 62: 1146–1147, 1988

    Article  PubMed  CAS  Google Scholar 

  • Bonati M, Galletti F, Volpi A, Cumetti C, Tognan G. Amiodarone in patients on long term dialysis. New England Journal of Medicine 308: 906, 1983

    PubMed  CAS  Google Scholar 

  • Borgreffe M, Leibner M, Briethardt G. Clinical electrophysiologic effects of combining Class I antiarrhythmic effects with amiodarone in drug refractory tachycardia. Circulation 74: 11–224, 1986

    Google Scholar 

  • Brown AK, Holt DW, Anderson V. A practical regimen for intravenous amiodarone. British Journal of Clinical Practice 40 (Suppl. 44): 135–138, 1986

    Google Scholar 

  • Burger A, Dinichett C, Nicod P, Jenny N, LeMarchand BP. Effect of amiodarone on serum triiodothyronine, reverse triiodothyronine, thyroxine and thyrotropin: a drug influencing peripheral metabolism of thyroid hormones. Journal of Clinical Investigation 58: 255–259, 1976

    Article  PubMed  CAS  Google Scholar 

  • Burkart F, Pfisterer M, Kiowski W, Burckhardt D, Follath F. Improved survival of patients with asymptomatic ventricular arrhythmias after myocardial infarction with amiodarone: a randomised, controlled trial. Circulation 80: 11–119, 1989

    Google Scholar 

  • Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomised trial of arrhythmia suppression after myocardial infarction. New England Journal of Medicine 321, 406–412, 1989

    Article  Google Scholar 

  • Charlier R, Delaunois G, Bauthier J, Deltour G. Dans la série des benzofurannes XI. Propriétés anti-arhythmiques de Tamiodarone. Cardiologia 54: 83–90, 1969

    Article  PubMed  CAS  Google Scholar 

  • CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. New England Journal of Medicine 316: 1429–1435, 1987

    Article  Google Scholar 

  • Cobbe SM, Manley BS. Cellular electrophysiology of amiodarone in cardiac ischaemia. British Journal of Clinical Practice 40 (Suppl.): 104–106, 1986

    Google Scholar 

  • Coumel P, Leclercq J-F, Leenhardt A. Arrhythmias as predictors of sudden death. American Heart Journal 114: 929–937, 1987

    Article  PubMed  CAS  Google Scholar 

  • Brown AK, Holt DW, Anderson V. A practical regimen for intravenous amiodarone. British Journal of Clinical Practice 40 (Suppl. 44): 135–138, 1986

    Google Scholar 

  • Cobbe SM, Manley BS. Cellular electrophysiology of amiodarone in cardiac ischaemia. British Journal of Clinical Practice 40 (Suppl.): 104–106, 1986

    Google Scholar 

  • Counihan PJ, McKenna WJ. Amiodarone for the treatment of cardiomyopathies. Choices in Cardiology 3 (Suppl. 3): 32–36, 1989

    Google Scholar 

  • Counihan PJ, McKenna WJ. Low dose amiodarone for the treatment of arrythmias in hypertrophic cardiomyopathy. Journal of Clinical Pharmacology 29 436–438, 1989

    PubMed  CAS  Google Scholar 

  • Cowan JC, Gardiner P, Reid DS, Newell DJ, Campbell RWF. Amiodarone in the management of atrial fibrillation complicating acute myocardial infarction. British Journal of Clinical Practice 40 (Suppl. 44) 155–161, 1986

    Google Scholar 

  • Cripps T, Counihan PJ, Frenneaux MP, Ward DE, Camm AJ, et al. Signal-averaged electrocardiography in hypertrophic cardiomyopathy. Journal of the American College of Cardiology 15, in press, 1990

  • Debbas NMG, Bexton RS, DuCailar C, Puech P, Camm AJ. Relationship between myocardial amiodarone concentration and the QT interval. Proceedings of the British Cardiac Society 1982

  • DiCarlo LA, Morady F, Sauve MJ, et al. Cardiac arrest and sudden death in patients treated with amiodarone for sustained ventricular tachycardia or ventricular fibrillation: risk stratification based on clinical variables. American Journal of Cardiology 55: 372–374, 1985

    Article  Google Scholar 

  • Dunn M, Kehoe RF, Glassroth J. Pulmonary toxicity during amiodarone therapy. Choices in Cardiology 3 (Suppl. 3): 40–43, 1989

    Google Scholar 

  • Facquet J, Nwet M, Grosgogeat Y, Alholme P, Vachon J. L’influence de l’amiodarone sur le rythme cardiaque et l’éléctrocardiogramme. Thérapie 25: 335–341, 1970

    PubMed  CAS  Google Scholar 

  • Flanagan RM, Storey GCA, Holt DW, Farmer PB. Identification and measurement of desethyl-amiodarone in blood-plasma specimens from amiodarone treated patients. Journal of Pharmacy and Pharmacology 34: 638–643, 1982

    Article  PubMed  CAS  Google Scholar 

  • Fogoros RN. Amiodarone induced refractoriness to cardioversion. Annals of Internal Medicine 100: 699–700, 1984

    PubMed  CAS  Google Scholar 

  • Fogoros RN, Fiedler SB, Elson JJ. The automatic implantable cardioverter defibrillator in drug refractory ventricular tachyarrhythmias. Annals of Internal Medicine 197: 635–641, 1987

    Google Scholar 

  • Foresti V, Pepe R, Parisio E, De Filippi G, Scolari N, et al. Angiotensin-converting enzyme as a possible marker for lung toxicity in amiodarone-treated patients. International Journal of Clinical Pharmacology Research 9: 261–267, 1989

    PubMed  CAS  Google Scholar 

  • Frank S, Braunwald E. Idiopathic hypertrophie sub-aortic stenosis: clinical analysis of 126 patients with emphasis on natural history. Circulation 37: 759–788, 1968

    Article  PubMed  CAS  Google Scholar 

  • Furberg CD, Hawkins CM, Lischstein E. Effect of propranolol in post infarction patients with mechanical or electrical complications. Circulation 49: 761–765, 1984

    Article  Google Scholar 

  • Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandenburg RO, et al. The natural history of idiopathic dilated cardiomyopathy. American Journal of Cardiology 47: 525–531, 1981

    Article  PubMed  CAS  Google Scholar 

  • Gold RO, Haffajee CI, Charos G, Sloan K, Baher S, et al. Amiodarone for refractory atrial fibrillation. American Journal of Cardiology 57: 124–127, 1986

    Article  PubMed  CAS  Google Scholar 

  • Graboys TB, Podila PJ, Lown B. The efficacy of amiodarone in refractory superventricular tachyarrhythmias. American Heart Journal 1983 106: 870–879, 1983

    Article  CAS  Google Scholar 

  • Haffajee CI, Love JC, Alpert JA, Asdourian GK, Sloan KC. Efficacy and safety of long-term amiodarone in treatment of cardiac arrhythmias: dosage experience. American Heart Journal 106: 935–942, 1983

    Article  PubMed  CAS  Google Scholar 

  • Hamer AWF, Arkles LB, Johns AJ. Beneficial effects of low dose amiodarone in patients with congestive cardiac failure: a placebo controlled trial. Journal of the American College of Cardiology 14: 1768–1774, 1989

    Article  PubMed  CAS  Google Scholar 

  • Harlel G, Louhija A, Kontinnen A. Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversion. Clinical Pharmacology and Therapeutics 15: 551–555, 1974

    Google Scholar 

  • Harris L, Hind CRK, McKenna WJ, Savage C, Krikler S, et al. Renal elimination of amiodarone and its desethyl metabolite. Postgraduate Medical Journal 59: 442–444, 1983

    Article  Google Scholar 

  • Harris L, McKenna WJ, Rowland E, Holt DW, Storey GCA et al. Side-effects of amiodarone therapy. Circulation 67: 45–51, 1983

    Article  PubMed  CAS  Google Scholar 

  • Heger JJ, Prystowsky EN, Miles WM, Zipes DP. Clinical use and pharmacology of amiodarone. Medical Clinics of North America 68: 1336–1339, 1984

    Google Scholar 

  • Heger JJ, Prystowsky EN, Zipes DP. Clinical efficacy of amiodarone dosage in the treatment of recurrent ventricular tachycardia and ventricular fibrillation. American Heart Journal 106: 887–893, 1983

    Article  PubMed  CAS  Google Scholar 

  • Herre JM, Sauve MJ, Malone P, Griffin JC, Helmy I, et al. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. Journal of the American College of Cardiology 13: 442–448, 1989

    Article  PubMed  CAS  Google Scholar 

  • Herre JM, Sauve MJ, Scheinman MM. Long-term results of amiodarone therapy. Clinical Cardiology 10 (Suppl.): 121–125, 1987

    Google Scholar 

  • Holt DW, Adams T, McKenna WJ, Anderson V, Brown AK. Accumulation of amiodarone and its desethyl metabolite in plasma. Proceedings of Cardiovascular Pharmacotherapy International Symposium Geneva 1985

  • Holt DW, Tucker GT, Jackson PR, Storey GCA. Amiodarone pharmacokinetics. American Heart Journal 106: 840–847, 1983

    Article  PubMed  CAS  Google Scholar 

  • Horowitz LN, Spielman SR, Greenspan AN, et al. Use of amiodarone in treatment of persistant paroxysmal atrial fibrillation resistant to quinidine therapy. Journal of the American College of Cardiology 6: 1402–1407, 1985

    Article  PubMed  CAS  Google Scholar 

  • Ingram DV. Occular effects in long term amiodarone therapy. American Heart Journal 106: 902–940, 1983

    Article  PubMed  CAS  Google Scholar 

  • Kappenberger LJ, Fromer MA, Steinbrunn W, Shenasa M. Efficacy of amiodarone in Wolff-Parkinson-White syndrome with rapid ventricular response via accessory pathway during atrial fibrillation. American Journal of Cardiology 54: 330–335, 1984

    Article  PubMed  CAS  Google Scholar 

  • Karen A, Tzivoni D, Gavish D, Levi J, Gottlieb S, et al. Aetiology, warning signs and therapy of torsade de pointes: a study of 10 patients. Circulation 64: 1167–1174, 1981

    Article  Google Scholar 

  • Kerin NZ, Blevins RD, Kerner N, Faitel K, Frumin H, et al. A low incidence of proarrhythmia using low dose amiodarone. Journal of Electrophysiology 2: 289–295, 1988

    Article  Google Scholar 

  • Kerin NZ, Blevins RD, Rubenfine M, Goldman L, Faitel K. The incidence, magnitude and time course of the amiodarone warfarin interaction. Archives of Internal Medicine 148: 1779–1781, 1988

    Article  PubMed  CAS  Google Scholar 

  • Krikler DM, Davies MJ, Rowland E, Goodwin JF, Evans RC. Sudden death in hypertrophic cardiomyopathy: associated accessory atrioventricular pathways. British Heart Journal 43: 245–251, 1980

    Article  PubMed  CAS  Google Scholar 

  • Kuo CS, Munakata K, Reddy CP, Suraviez B. Characteristics and possible mechanism of ventricular arrhythmia dependent on the dispersion of action potential durations. Circulation 67: 1356–1367, 1983

    Article  PubMed  CAS  Google Scholar 

  • Lalloz MRA, Byfield PGH, Greenwood RM, Himsworth RL. Binding of amiodarone by serum proteins and the effects of drugs, hormones and other interacting ligands. Journal of Pharmacy and Pharmacology 36: 366–372, 1984

    Article  PubMed  CAS  Google Scholar 

  • Latina R, Reginato R, Burlingame AL, Kates RE. High performance liquid Chromatographic isolation and fast atom bombardment mass spectrometric identification of di-N-desethyl-amiodarone, a new metabolite of amiodarone in the dog. Biomedical Mass Spectrometry 11: 466–467, 1984

    Article  Google Scholar 

  • Lim PK, Trewby PN, Storey GCA, Holt DW. Neuropathy and fatal hepatitis in a patient receiving amiodarone. British Medical Journal 288: 1638–1639, 1984

    Article  PubMed  CAS  Google Scholar 

  • Magro SA, Lawerence EC, Wheeler SH, Krafchek J, Lin H, et al. Amiodarone pulmonary toxicity: prospective evaluation of serial pulmonary function tests. Journal of the American College of Cardiology 12: 781–788, 1988

    Article  PubMed  CAS  Google Scholar 

  • Manicardi V, Bertorelli G, Pesci A, Bellodi G. Low dose amiodarone-induced pneumonitis: evidence of an immunologie pathogenic mechanism. American Journal of Medicine 86: 134–135, 1989

    Article  PubMed  CAS  Google Scholar 

  • Marcus FI. Drug interactions with amiodarone. American Heart Journal 106: 924–929, 1983

    Article  PubMed  CAS  Google Scholar 

  • Martin A, Benbow CJ, Leach C, Bailey RJ. Comparison of amiodarone and disopyramide in control of paroxysmal atrial fibrillation and atrial flutter. British Journal of Clinical Practice 40(Suppl. 44) 52–57, 1986

    Google Scholar 

  • Martino E, Safran M, Aghini-Lombardi F, et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Annals of Internal Medicine 101: 28–34, 1984

    PubMed  CAS  Google Scholar 

  • McGovern B, Garan H, Kelly E, Ruskin JN. Adverse reactions during treatment with amiodarone hydrochloride. British Medical Journal 287: 175–180, 1983

    Article  PubMed  CAS  Google Scholar 

  • McKenna WJ and Goodwin JF. The natural history of hypertrophic cardiomyopathy. In Harvey (Ed.) Current problems in cardiology, Vol. 4, pp.5–26, Year Book Medical Publishers, Chicago, 1981

    Google Scholar 

  • McKenna WJ, Adams KM, Poloniecki JD, Dickie S, Oakley CM, et al. Long-term survival with amiodarone in patients with hypertrophie cardiomyopathy and ventricular tachycardia. Abstract, Circulation 80: II–7, 1989

    Google Scholar 

  • McKenna WJ, Deanfield JE. Hypertrophie cardiomyopathy: an important cause of sudden death. Archives of Disease in Childhood 59: 971–975, 1984

    Article  PubMed  CAS  Google Scholar 

  • McKenna WJ, England D, Doi YL, Deanfield JE, Okaley CM, et al. Arrhythmia in hypertrophie cardiomyopathy: I. Influence on prognosis. British Heart Journal 46: 168–172, 1981

    Article  PubMed  CAS  Google Scholar 

  • McKenna WJ, Franklin RCG, Nihoyannopoulos P, Robinson KC, Deanfield JE. Arrhythmia and prognosis in infants, children and adolescents with hypertrophie cardiomyopathy. Journal of the American College of Cardiology 11: 147–153, 1988

    Article  PubMed  CAS  Google Scholar 

  • McKenna WJ, Harris L, Mulrow JP, Rowland E, Holt DW. Amiodarone dose titration: a method to minimise side effects during long term therapy. British Journal of Clinical Practice 40(Suppl. 44): 121–127, 1986

    Google Scholar 

  • McKenna WJ, Harris L, Rowland E, Kleinebenne A, Krikler DM, et al. Amiodarone for long term management in hypertrophic cardiomyopathy. American Journal of Cardiology 54: 802–810, 1984

    Article  PubMed  CAS  Google Scholar 

  • McKenna WJ, Harris L, Rowland E, Whitelaw A, Storey GCA, et al. Amiodarone therapy during pregnancy. American Journal of Cardiology 51: 1231–1233, 1983

    Article  PubMed  CAS  Google Scholar 

  • McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. British Heart Journal 53: 412–416, 1985

    Article  PubMed  CAS  Google Scholar 

  • Meinhertz T, Treese N, Kasper W, Geibel A, Hofmann T, et al. Determinants of prognosis in idiopathic dilated cardiomyopathy as determined by programmed electrical stimulation. American Journal of Cardiology 56: 337–341, 1985

    Article  Google Scholar 

  • Moslow ND, Vrobel TR, Noon D, Rakita L, Pharmacology of amiodarone: practical considerations regarding dosing. Choices in Cardiology (Suppl. 3): 3–5, 1989

  • Munoz A, Karila P, Gallay P, Zellelmeier F, Messner P, et al. A randomised haemodynamic comparison of intravenous amiodarone with and without Tween 80. European Heart Journal 9: 142–148, 1988

    PubMed  CAS  Google Scholar 

  • Naccarelli GV, Crandell J, Dougherty AH, Fitzgerald DM, Rinkenberger RL. Amiodarone therapy for supraventricular tachycardia. Choices in Cardiology 3 (Suppl. 3): 28–31, 1989

    Google Scholar 

  • Naccarelli GV, Rinkenberger RL, Dougherty AH, Fitzgerald DM. Adverse effects of amiodarone: pathogenesis, incidence and management. Medical Toxicology and Adverse Drug Experience 4: 246–253, 1989

    PubMed  CAS  Google Scholar 

  • Naccarelli GV, Rinkenberger RL, Dougherty AH, Giebel RA. Amiodarone: pharmacology and antiarrhythmic and adverse effects. Pharmacotherapy 298–313, 1985

  • Olshausen KV, Stienen U, Math D, et al. Long term prognostic significance of ventricular arrhythmia in dilated cardiomyopathy. American Journal of Cardiology 61: 146–151, 1988

    Article  PubMed  CAS  Google Scholar 

  • Olsson SB, Brorson L, Vamauskas E. Class III antiarrhythmic action in man: observations from monophasic action potential recordings and amiodarone treatment. British Heart Journal 35: 1255–1259, 1980

    Article  Google Scholar 

  • Parbaix S, Berger Y, Desager JP, Pacco M, Harvengt C. Absolute bioavailability of amiodarone in normal subjects. Clinical Pharmacology and Therapeutics 37: 118–123, 1985

    Article  Google Scholar 

  • Paul V, Griffith M, Ward DE, Camm AJ. Adjuvent xamoterol or metoprolol in patients with malignant ventricular arrhythmias resistant to amiodarone. Lancet 11: 302–304, 1989

    Article  Google Scholar 

  • Pollak T, Sharma AD, Carruthers SG. Elevation of serum total cholesterol and triglyceride levels during amiodarone therapy. American Journal of Cardiology 62: 562–565, 1988

    Article  PubMed  CAS  Google Scholar 

  • Polster P, Broekhuysen J. The adrenergic antagonism of amiodarone. Biochemical Pharmacology 25: 131–134, 1976

    Article  PubMed  CAS  Google Scholar 

  • Pourcell S, Ireton J, Calencia-Mayoral P, et al. Amiodarone-as-sociated phospholipidosis and fibrosis of the liver. Gastroenterology 86: 926–936, 1984

    Google Scholar 

  • Raeder EA, Podrid PJ, Lown B. Side effects and complications of amiodarone therapy. American Heart Journal 109: 975–983, 1985

    Article  PubMed  CAS  Google Scholar 

  • Rakita L, Sobol SM, Mostow N, Vrobel T. Amiodarone pulmonary toxicity. American Heart Journal 106: 906–914, 1983

    Article  PubMed  CAS  Google Scholar 

  • Robinson K, Johnston A, Walker S, Holt DW, McKenna WJ. Effects of amiodarone on the kinetics of antipyrine. American Journal of Cardiology 63: 991–992, 1989

    Article  PubMed  CAS  Google Scholar 

  • Robinson K, Mulrow JP, Rowland E, McKenna WJ. Long term effects of amiodarone on hepatic function. American Journal of Cardiology 64: 95–96, 1989

    Article  PubMed  CAS  Google Scholar 

  • Rotmensch HH, Belhassen B, Swanson BN, et al. Steady state serum amiodarone concentration: relationships with antiar-rhythmic efficacy and toxicity. Annals of Internal Medicine 101: 462–469, 1984

    PubMed  CAS  Google Scholar 

  • Rowland E, Krikler DM. Electrophysiological assessment of amiodarone in patients with resistant supraventricular arrhythmias. British Heart Journal 44: 82–89, 1980

    Article  PubMed  CAS  Google Scholar 

  • Rowland E, McKenna WJ, Holt DW, Harris L, Krikler DM. Control of the ventricular response with oral amiodarone in patients with rapidly conducted atrial fibrillation complicating the Wolff-Parkinson-White syndrome. Circulation 64 (Suppl. II): IV–1317, 1981

    Google Scholar 

  • Rowland E, McKenna WJ, Krikler DM. Amiodarone for conversion of established atrial fibrillation and flutter. British Journal of Clinical Practice 40 (Suppl. 44) 39–41, 1986

    Google Scholar 

  • Saal AK, Warner JA, Greene HL, Sears GK, Graham AL. Effect of amiodarone on serum quinidine and procainamide levels. American Journal of Cardiology 53: 1264–1267, 1984

    Article  PubMed  CAS  Google Scholar 

  • Savage DD, Seides SF, Maron BJ, Myers DM, Epstein SE. Prevalence of arrhythmia during 24 hour electrocardiographic monitoring and exercise testing in patients with obstructive and non obstructive hypertrophic cardiomyopathy. Circulation 59: 866–875, 1979

    Article  PubMed  CAS  Google Scholar 

  • Schwartz A, Shen E, Morady F, Gillespie K, Scheinman M, et al. Haemodynamic effects of intravenous amiodarone in patients with depressed left ventricular function and recurrent ventricular tachycardia. American Heart Journal 106: 848–856, 1983

    Article  PubMed  CAS  Google Scholar 

  • Sclarovsky S, Lewin RF, Kracoff O, Strasberg B, Arditta A, et al. Amiodarone induced polymorphous ventricular tachycardia. American Heart Journal 105: 6–12, 1983

    Article  PubMed  CAS  Google Scholar 

  • Shea P, Lal R, Kimm SS, Schechtman K, Ruffy R. Flecainide and amiodarone interaction. Journal of the American College of Cardiology 7: 1127–1130, 1986

    Article  PubMed  CAS  Google Scholar 

  • Sheldon RS, Mitchell B, Duff HJ, Wyse DG, Manyari DE. Right and left ventricular function during chronic amiodarone therapy. American Journal of Cardiology 62: 736–740, 1988

    Article  PubMed  CAS  Google Scholar 

  • Sicart M, Besse P, Chossat A, Bricaud M. Action haemodynamique de l’amiodarone intraveineuse chez l’homme. Archives des Maladies du Coeur et des Vaisseaux 70: 219–227, 1977

    PubMed  CAS  Google Scholar 

  • Singh BN, Nadamanee K. Amiodarone and thyroid function: clinical implications during antiarrhythmic therapy. American Heart Journal 106: 857–868, 1983

    Article  PubMed  CAS  Google Scholar 

  • Singh BN, Vaughan-Williams EM. The effect of amiodarone, a new antianginal drug on cardiac muscle. British Journal of Pharmacology 39: 657–667, 1970

    Article  PubMed  CAS  Google Scholar 

  • Singh BN. When is QT prolongation antiarrhythmic and when is it proarrhythmic? American Journal of Cardiology 63: 867–869, 1989

    Article  PubMed  CAS  Google Scholar 

  • Stafford WJ, Trohman RG, Bilsker M, Zaman L, Castellanos A, et al. Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy. Journal of the American College of Cardiology 7: 701–704, 1986

    Article  PubMed  CAS  Google Scholar 

  • Staiger C, Javernig R, Vries JD, Weber E. Influence of amiodarone on antipyrine pharmacokinetics in three patients with ventricular tachycardia. British Journal of Clinical Pharmacology 18: 263, 1984

    Article  PubMed  CAS  Google Scholar 

  • Stewart RA, McKenna WJ, Poloniecki JD, Michelson JK, Das SK, et al. Prospective, randomised, placebo-controlled trial of low dose amiodarone in patients with severe heart failure and frequent ventricular ectopy. European Heart Journal 10 (Suppl.): 229, 1989

    Google Scholar 

  • Storey GCA, Holt P, Curry PVL, Holt DW. High performance liquid chromatography measurement of amiodarone and its desethyl metabolite: methodology and preliminary observations. Therapeutic Drug Monitoring 4: 385–388, 1982

    Article  PubMed  CAS  Google Scholar 

  • Szekely P, Sideras DA, Batson GA. Maintenance of sinus rhythm after atrial fibrillation. British Heart Journal 32: 741–746, 1970

    Article  PubMed  CAS  Google Scholar 

  • Tartini R, Kappenberger L, Steinbrunn W, Mayer UA. Dangerous interactions between amiodarone and quinidine. Lancet 1: 1327–1330, 1982

    Article  PubMed  CAS  Google Scholar 

  • Tonet JL, Bernardeau C, Lechat Ph, Frank R, Touzet I, et al. Comparison between the efficacy of amiodarone and quinidine in the treatment of atrial cardiac arrhythmias. British Journal of Clinical Practice 40 (Suppl. 44): 42–45, 1986

    Google Scholar 

  • Tonet J, Frank R, Fontaine G, Grosgeat Y. Efficacy and safety of low dose beta blocking agents combined with amiodarone in refractory ventricular tachycardia. PACE 11: 1984–1989, 1988

    Article  PubMed  CAS  Google Scholar 

  • Vastesaeger M, Guillot P, Rasson G. Étude clinique d’une nouvelle médication antiangoreuse. Acta Cardiologica 51: 767–785, 1967

    Google Scholar 

  • Vaughan-Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. Journal of Clinical Pharmacology 24: 129–147, 1984

    PubMed  CAS  Google Scholar 

  • Vaughan-Williams EM. Classification of antiarrhythmic drugs. In Sandoe et al. (Eds) Cardiac arrhythmias, AB Astra, Sodertalje, 1970

  • Ward DE, Camm AJ, Spurrell RAJ. Clinical antiarrhythmic effects of amiodarone in patients with resistant paroxysmal tachycardias. British Heart Journal 44: 91–95, 1980

    Article  PubMed  CAS  Google Scholar 

  • Weetman AP, Bhandal SK, Burrin JM, Robinson K, McKenna WJ. Amiodarone and thyroid autoimmunity in the United Kingdom. British Medical Journal 297: 33, 1988

    Article  PubMed  CAS  Google Scholar 

  • Wellens HJJ, Brugada P, Abdollah H. Effect of amiodarone in paroxysmal supraventricular tachycardia with or without Wolff-Parkinson-White syndrome. American Heart Journal 106: 876–880, 1983

    Article  PubMed  CAS  Google Scholar 

  • Wellens HJJ, Lie KE, Bar FW, Wesdorp JW, Dohman HJ, et al. Effect of amiodarone in the Wolff-Parkinson-White Syndrome. American Journal of Cardiology 38: 189–194, 1976

    Article  PubMed  CAS  Google Scholar 

  • Werner EG, Olanow CW. Amiodarone-Parkinsonism. Clinical Alert 13: 172–173, 1989

    Google Scholar 

  • Whatling A. Investigation into the prevention of amiodarone photosensitivity using topical sunscreening agents and oral beta carotene, MSc Thesis, University of Longon 1989

  • Wood DL. Efficacy of amiodarone in malignant ventricular arrhythmias. Choices in Cardiology 3 (Suppl. 3): 10–12, 1989

    Google Scholar 

  • Zachary CB, Slater DN, Holt DW, Storey GCA, MacDonald DM. The pathogenesis of amiodarone-induced pigmentation and photosensitivity. British Journal of Dermatology 110: 451–456, 1984

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiological Sciences, St George’s Hospital Medical School, Cranmer Terrace, London, SW17 ORE, England

    Peter J. Counihan &  William J. McKenna

Authors
  1. Peter J. Counihan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William J. McKenna
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Counihan, P.J., McKenna, W.J. Risk-Benefit Assessment of Amiodarone in the Treatment of Cardiac Arrhythmias. Drug-Safety 5, 286–304 (1990). https://doi.org/10.2165/00002018-199005040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199005040-00005

Keywords

Search

Navigation